|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Novo Nordisk |
| Information provided by: | Novo Nordisk |
| ClinicalTrials.gov Identifier: | NCT00426803 |
Purpose
This trial is conducted in North America, Europe, Asia and Oceania.
The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.
| Condition | Intervention | Phase |
|
Spontaneous Intracerebral Haemorrhage |
Drug: Recombinant Factor VIIa |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Efficacy and Safety of Recombinant Factor VIIa in Acute Intracerebral Haemorrhage |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 36 Study Locations |
| Novo Nordisk |
More Information
| Study ID Numbers: | F7ICH-1371 |
| First Received: | January 24, 2007 |
| Last Updated: | January 26, 2007 |
| ClinicalTrials.gov Identifier: | NCT00426803 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|